Table 4 The incidence/prevalence of the following problems are not well defined in patients undergoing treatment for DTC
From: Treatment related morbidity in differentiated thyroid cancer–a survey of clinicians
Complication (number of responders) | Strongly agree | Disagree | Neutral/don’t know | Agree | Strongly agree |
|---|---|---|---|---|---|
Temporary hypocalcaemia (118) | 16 (13.6%) | 47 (39.8%) | 8 (6.8%) | 42 (35.6%) | 5 (4.2%) |
Long term hypocalcaemia (118) | 16 (13.6%) | 50 (42.4%) | 9 (7.6%) | 37 (31.4%) | 6 (5.1%) |
Significant voice change (117) | 14 (12.0%) | 42 (35.9%) | 12 (10.3%) | 42 (35.9%) | 7 (6.0%) |
Symptoms/poor quality of life from TSH suppression (118) | 6 (5.1%) | 10 (8.5%) | 24 (20.3%) | 62 (52.5%) | 16 (13.6%) |
Bone/CVS complications from TSH suppression (118) | 5 (4.2%) | 10 (8.5%) | 27 (22.9%) | 59 (50.0%) | 17 (14.4%) |